Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in Gaucher Disease Type 3 (GD3)
NCT05222906Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of venglustat in Gaucher disease type 3 (2 arms), sponsored by Sanofi. Primary endpoints: Scale for Assessment and Rating of Ataxia modified total score at 52 weeks and Repeatable Battery for the Assessment of Neuropsychological Status total scale index score at 52 weeks. Started Apr 2022; status: active, not recruiting.
02
Drugs
venglustat
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT05222906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222906.